Abstract 876P
Background
Despite surgical resection, Oral Potentially Malignant Disorders show a rate of malignant transformation varying from 3% to 17.5%. Clinical and histological factors outside dysplasia and previous oral cavity carcinoma failed to identify OPMDs at higher risk of malignant transformation (MF). We previously identified six clusters of transcriptomic data able to stratify Head and Neck Squamous Cell Carcinoma (HNSCC) that also applied to OPMD. The primary objective of the current study was to validate the stratification by the transcriptional signature in an independent series of dysplastic OPMD.
Methods
We collected a retrospective series (3/1996 to 11/2019) of completely excised OPMDs with any grade of dysplasia at the University of Brescia. Clinical/histological data were retrieved. Library preparation for gene expression profiling was conducted QuantSeq 3'mrna-seq (Lexogen) and pooled libraries were sequenced by NextSeq500 (Illumina). Finally, previously identified molecular clusters based on main biological characteristics and de-regulated signaling pathways were associated with the risk of MF.
Results
We identified 106 consecutive patients with OPMDs. Of these, 66 had available material for gene expression analysis. A slight majority were male (53.4%), with a median age of 65 years (33-95); 17% had a previous diagnosis of HNSCC. With a median follow-up of 53 months (IQR 91), 23% experienced a MF with a median time to transformation of 30 months (3—195). After stratification based on our previously reported clusters, OPMDs were classified as mesenchymal, hypoxia, defense response, classical, and immunoreactive clusters constituted 8%, 15%, 27%, 9%, and 41% of our cohort, respectively. Hypoxia cluster showed a higher risk of malignant transformation (p<0.0001).
Conclusions
OPMDs gene expression clustering allows stratifying patients according to different risk of MF. Among them, hypoxia cluster had the highest probability of cancerization. A more in-depth analysis of this cluster is required, both to better characterize the mechanisms of MF and to develop customized prevention strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Oncology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili, 25123 Brescia, Italy.
Funding
Funded by AIRC (IG 21740 to PB).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
910P - Machine learning-based survival prediction model for postoperative parotid mucoepidermoid carcinoma
Presenter: Chen Zihan
Session: Poster session 12
911P - Post-radiotherapy (RT) Epstein-Barr virus (EBV) DNA dynamics identifies optimal timepoint for stratification of high-risk nasopharyngeal carcinoma (NPC)
Presenter: Janice Ser Huey Tan
Session: Poster session 12
912P - Toripalimab in combination with anlotinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: The interim analysis of the single-arm, phase II TORAL study
Presenter: QingQing Cai
Session: Poster session 12
916P - Reducing radiation-induced temporal lobe injury by changing tumor prescription dose in nasopharyngeal carcinoma
Presenter: Xiao Xiao
Session: Poster session 12
917P - Radiation-induced nasopharyngeal necrosis in locally-recurrent nasopharyngeal carcinoma patients after re-radiotherapy
Presenter: Runda Huang
Session: Poster session 12
918P - SPP1-related M2 macrophage signatures predict prognosis and immunotherapy response in patients with nasopharyngeal carcinoma
Presenter: Li Ying
Session: Poster session 12
919P - A prognostic model of nasopharyngeal carcinoma based on 18F-FDG PET-CT radiomic parameters and clinical characteristics of patients
Presenter: Wu xi
Session: Poster session 12
920P - Envafolimab plus chemoradiotherapy for locally advanced nasopharyngeal carcinoma (NPC), a prospective, single-armed phase II trial
Presenter: Xiaohui Wang
Session: Poster session 12
921P - HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer
Presenter: Lisle Nabell
Session: Poster session 12